Early postoperative intraperitoneal Adriamycin as an adjuvant treatment for visceral and retroperitoneal sarcoma

  • Paul H. Sugarbaker
Part of the Cancer Treatment and Research book series (CTAR, volume 81)


Visceral and retroperitoneal sarcoma represents an unsolved problem in oncology with a majority of patients going on to die of their disease despite an aggressive surgical approach. This cancer fails its surgical treatment both at systemic sites and within the abdominal cavity. Local recurrence rates are extremely high with retroperitoneal and pelvic sarcoma. Approximately 8 out of 10 patients who recur are shown to have local recurrence with the resection site involved in the recurrent malignant process [1]. Also, a majority of the patients who recur have peritoneal seeding (Sarcomatosis) in addition to the resection site recurrence [2]. These local recurrences are more commonly seen in patients with retroperitoneal and pelvic sarcomas as opposed to visceral sarcoma. Peritoneal seeding plus liver metastases are the sites of treatment failure most commonly seen with visceral sarcoma.


Peritoneal Carcinomatosis Early Postoperative Period Intraperitoneal Chemotherapy Resection Site Early Postoperative Intraperitoneal Chemotherapy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Glenn J, Sindelar WF, Kinsella TJ, Glatstein E, Tepper JE, Costa J, Baker AR, Sugarbaker Ph, Brennan MF, Seipp CA, Wesley R, Young RC, Rosenberg SA. Results of multimodality therapy of resectable soft tissue sarcomas of the retroperitoneum. Surgery 1985;97:316–325.PubMedGoogle Scholar
  2. 2.
    Sugarbaker TA, Chang D, Koslowe P, Sugarbaker PH. Patterns of spread of recurrent intraabdominal sarcoma. In Sugarbaker PH, ed. Peritoneal Carcinomatosis: Principles of management. Boston: Kluwer Academic Publishers, 1996, pp 65–77.Google Scholar
  3. 3.
    Kinsella TJ, Sindelar WF, Lack E, et al. Preliminary results of a randomized study of adjuvant radiation therapy in resectable adult retroperitoneal soft tissue sarcomas. J Clin Oncol 1988;6:18–25.PubMedGoogle Scholar
  4. 4.
    Fernandez-Trigo V, Sugarbaker PH. Sarcomas involving the abdominal and pelvic cavity. Tumori 1993;79:77–91.PubMedGoogle Scholar
  5. 5.
    Cunliffe WJ, Sugarbaker PH. Gastrointestinal malignancy: Rationale for adjuvant therapy using early postoperative intraperitoneal chemotherapy (EPIC). Br J Surg 1989;76:1082–1090.PubMedCrossRefGoogle Scholar
  6. 6.
    Chang AE, Rosenberg SA, Glatstein EJ, Antman KH. Sarcomas of soft tissues. In De Vita VT, Hellman S, Rosenberg SA, eds Principles of Practice of Oncology, 3rd ed Philadelphia: JB Lippincott, 1989, p 1385.Google Scholar
  7. 7.
    Park JG, Kramer BS, Steinberg SM, Carmichael J, Collins JM, Minna JD, Gajdar AF. Chemosensitivity testing of human colorectal carcinoma cells using a tetrosolium-based colorimetric assay. Cancer Res 1987;47:5875–5879.PubMedGoogle Scholar
  8. 8.
    Sugarbaker PH, Sweatman TW, Graves T, Cunliffe W, Israel M. Early postoperative intraperitoneal Adriamycin: Pharmacologic studies and a preliminary clinical report. Reg Cancer Treat 1991;4:127–171.Google Scholar
  9. 9.
    Speyer JL, Sugarbaker PH, Collins JM, Dedrick RL, Klecker RW Jr, Meyers CE. Portal levels and hepatic clearance of 5-fluorouracil after intraperitoneal administration in humans. Cancer Res 1981;41:1916–1922.PubMedGoogle Scholar
  10. 10.
    Ozols RF, Young RC, Speyer JL, Sugarbaker PH, Green R, Jenkins J, Meyers CE. Phase I 1 pharmacologic studies of Adriamycin administered intraperitoneally to patients with ovarian ca cer. Cancer Res 1982;42:4265–4269.PubMedGoogle Scholar
  11. 11.
    Roboz J, Jacobs AJ, Holland JF, Deppe G, Cohen CJ. Intraperitoneal infusion of doxorubicin in the treatment of gynecologic carcinomas. Med Pediatr Oncol 1981;9:245–250.PubMedCrossRefGoogle Scholar
  12. 12.
    Chang BK. Tissue distribution of Adriamycin administered intraperitoneally vs. intravenously, with special emphasis on the pancreas. Bull Cancer (Paris) 1982;69:172–175.Google Scholar

Copyright information

© Kluwer Academic Publishers, Boston 1996

Authors and Affiliations

  • Paul H. Sugarbaker

There are no affiliations available

Personalised recommendations